More than 500 patients with inoperable liver metastases from primary colorectal cancer were enrolled and the primary results are expected in 2014.
Sirtex Medical president Mike Mangano said that the company was committed to large, randomised controlled trials to confirm the results from various, smaller, peer-reviewed studies that have established the effectiveness of SIR-Spheres microspheres.
"We anticipate that the data from the SIRFLOX study will provide sufficient proof to the oncology community that combining chemotherapy and internal radiation therapy earlier in the treatment algorithm will benefit patients," Mangano added.
The study is designed to assess the effectiveness of first-line treatment strategy of standard-of-care chemotherapy along with SIR-Spheres microspheres versus chemotherapy alone in delaying cancer progression in the patient population.
SIRFLOX investigator and University of Maryland School of Medicine vascular and interventional radiology division interim director said, "We are excited to be the top enrolling US site in this landmark study and look forward to seeing the results, which we believe will help further guide the oncology community in best practice treatment for liver tumours from metastatic colorectal disease."